Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anlotinib
- Angiogenesis
- Antineoplastic Agents
- Carcinoma
- Carcinoma, Ovarian Epithelial
- Endocrine System Diseases
- Ovarian Diseases
- Neoplasms, Glandular and Epithelial
- Fallopian Tube Neoplasms
- Genital Diseases, Female
- Ovarian Neoplasms
- Genital Neoplasms, Female
- Neoplasms by Histologic Type
- Neoplasms by Site
- Tyrosine Kinase Inhibitor
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
This study is a single-arm, multicenter, exploratory phase II study to observe the efficacy and safety of anlotinib combined with carboplatin/paclitaxel as first-line treatment in patients with advanced ovarian cancer. The primary end point are progression free survival; the secondary end points inc...
This study is a single-arm, multicenter, exploratory phase II study to observe the efficacy and safety of anlotinib combined with carboplatin/paclitaxel as first-line treatment in patients with advanced ovarian cancer. The primary end point are progression free survival; the secondary end points include objective response rate, disease control rate, overall survival and safety. The subjects in this study: patients with newly diagnosed advanced (FIGO stage III-IV) ovarian cancer, including histologically or pathologically confirmed high-grade serous ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma
Tracking Information
- NCT #
- NCT04807166
- Collaborators
- Not Provided
- Investigators
- Study Chair: Wenjun Cheng, MD,PhD The First Affiliated Hospital with Nanjing Medical University
Get Well Soon